Latest Earnings Analysis

• Aurora Cannabis (ACB) Q1 2025: Medical Cannabis Margins Hit 69% as Global Expansion Accelerates
  August 07, 2024 · ACB
• ACMR Q2 2024: ECP, Furnace Revenue Doubles, New $3B Target Signals Global Ambition
  August 07, 2024 · ACMR
• Alector (ALEC) Q2 2024: $503M Cash Runway Supports Late-Stage Neuro Pipeline Through 2026
  August 07, 2024 · ALEC
• AACG Q2 2024: Portfolio Training Revenue Jumps 42%, Driving Margin Expansion
  August 07, 2024 · AACG
• ARI Q2 2024: $90M Anticipated CECL Reserve Signals Risk Reset as Portfolio Holds at $8.3B
  August 07, 2024 · ARI
• Boot Barn (BOOT) Q1 2025: Merchandise Margin Expands 100bps as Exclusive Brands Hit 38%
  August 07, 2024 · BOOT
• The Andersons (ANDE) Q2 2024: EBITDA Falls 32% as Margin Compression Hits Renewables and Nutrients
  August 07, 2024 · ANDE
• Bumble (BMBL) Q2 2024: Paying Users Rise 14% as Strategic Reset Slows Near-Term Monetization
  August 07, 2024 · BMBL
• Amtech Systems (ASYS) Q3 2024: $7M Cost Savings Reshape Margin Profile as Demand Bottoms
  August 07, 2024 · ASYS
• Angi (ANGI) Q2 2024: Angie Profit Surges as Revenue Declines 15% on Quality Over Volume Pivot
  August 07, 2024 · ANGI
• Aquestive Therapeutics (AQST) Q2 2024: Revenue Up 52% on Deferred Recognition, Anafilm Nears NDA Milestone
  August 07, 2024 · AQST
• Allogene (ALLO) Q2 2024: $445M Cash Extends Runway as Alpha-3 CAR-T Sites Expand
  August 07, 2024 · ALLO
• Amphastar (AMPH) Q2 2024: Gross Margin Lifts to 52.2% as Baximi and Epinephrine Outperform
  August 07, 2024 · AMPH
• Albany International (AIN) Q2 2024: $900M New Orders Propel AEC Backlog to $1.2B Amid Margin Pressures
  August 07, 2024 · AIN
• American Financial Group (AFG) Q2 2024: Renewal Rate Increases Hit 8% as Underwriting Discipline Tightens
  August 07, 2024 · AFG
• BAM Q2 2024: Fee-Bearing Capital Climbs 17% as Insurance and Credit Drive Platform Leverage
  August 07, 2024 · BAM
• Alta Equipment Group (ALTG) Q2 2024: Product Support Hits $144M as Construction Margins Compress
  August 07, 2024 · ALTG
• Blue Bird (BLBD) Q3 2024: EV Backlog Jumps 17% as Alternative Power Drives 14.5% Margin Breakout
  August 07, 2024 · BLBD
• Atkore (ATKR) Q3 2024: Steel Conduit Imports Surge to 20%, Forcing Margin Reset
  August 06, 2024 · ATKR
• Airgain (AIRG) Q2 2024: Consumer Sales Jump $1.3M as Wi-Fi 7 and FWA Ramp, AC Fleet Set to Drive Q4
  August 06, 2024 · AIRG
• Astera Labs (ALAB) Q2 2024: Revenue Surges 619% as PCIe and Ethernet Content Expands with AI Platform Complexity
  August 06, 2024 · ALAB
• ALCO Q3 2024: Citrus Volume Up 17% as Land Monetization Accelerates
  August 06, 2024 · ALCO
• Alight (ALIT) Q2 2024: Cloud Migration Cuts $75M in Costs, Margin Surges to 25%
  August 06, 2024 · ALIT
• BioXcel Therapeutics (BTAI) Q2 2024: EGALMI Revenue Surges 141% as Home Agitation Trials Advance
  August 06, 2024 · BTAI
• Alto Ingredients (ALTO) Q2 2024: Pekin Gross Profit Surges 150% as Plant Upgrades Unlock Margin Leverage
  August 06, 2024 · ALTO
• Apple Hospitality REIT (APLE) Q2 2024: Share Repurchases Reach $23M as Rate Sensitivity Tempers RevPAR Growth
  August 06, 2024 · APLE
• Bentley Systems (BSY) Q2 2024: Asset Analytics ARR Surges to Eight Digits, Driving Next-Gen Growth
  August 06, 2024 · BSY
• ALX Q2 2024: $350M Uniqlo Sale and 1.6M SF Leased Signal Liquidity and Demand Turn
  August 06, 2024 · ALX
• Bowhead Specialty (BOW) Q2 2024: E&S Premiums Surge 50% as Cycle-Resilient Model Gains Traction
  August 06, 2024 · BOW
• Aramark (ARMK) Q3 2024: International AOI Jumps 41%, GPO Scale Drives Margin Upside
  August 06, 2024 · ARMK
• Builders FirstSource (BLDR) Q2 2024: $990M Buyback Amid 31% Multifamily Decline Signals Margin Resilience
  August 06, 2024 · BLDR
• ACRE Q2 2024: Risk-Rated 4/5 Loans Hit $477M as Portfolio Resolution Takes Priority
  August 06, 2024 · ACRE
• Amgen (AMGN) Q2 2024: Rare Disease Revenue Tops $1.1B, Pipeline Investment Reshapes Margin Outlook
  August 06, 2024 · AMGN
• AECOM (ACM) Q3 2024: Digital Consulting Revenue Jumps 70%, Expanding Secular Growth Platform
  August 06, 2024 · ACM
• BellRing Brands (BRBR) Q3 2024: Premier Protein Sales Jump 20% as Capacity Expansion Unlocks Growth
  August 06, 2024 · BRBR
• ANI Pharmaceuticals (ANIP) Q2 2024: Cortrophin Gel Revenues Double, Rare Disease Now 45% of Pro Forma Sales
  August 06, 2024 · ANIP
• Azenta (AZTA) Q3 2024: EBITDA Margin Expands 440bps as Automation and Cost Actions Accelerate
  August 06, 2024 · AZTA
• ADC Therapeutics (ADCT) Q2 2024: Operating Expenses Down 23% as Commercial Profitability Reached and Pipeline Advances
  August 06, 2024 · ADCT
• Boise Cascade (BCC) Q2 2024: General Line Mix Hits 42%, Offsetting EWP Price Pressure
  August 06, 2024 · BCC
• BlackLine (BL) Q2 2024: Strategic Products Hit 28% of Sales, Elevating Platform Mix
  August 06, 2024 · BL
• ADEA (ADEA) Q2 2024: $3.4M Interest Savings Unlocks Capital Flexibility for IP Expansion
  August 06, 2024 · ADEA
• Avient (AVNT) Q2 2024: Organic Sales Rise 5% as Volume Growth Returns to Core Segments
  August 06, 2024 · AVNT
• Adient (ADNT) Q3 2024: $800M Metals Exit Reshapes Margin Path as EMEA Drags
  August 06, 2024 · ADNT
• Baldwin Group (BWIN) Q2 2024: UCTS Organic Revenue Jumps 37% as MGA Premiums Top $1B
  August 06, 2024 · BWIN
• ADTRAN (ADTN) Q2 2024: Operating Margin Rises 334bps as Inventory Headwinds Ease
  August 06, 2024 · ADTN
• Ascent (ACNT) Q2 2024: 28% Cost Reduction Unlocks Margin Rebound as Self-Help Drives Turnaround
  August 06, 2024 · ACNT
• Addus HomeCare (ADUS) Q2 2024: Personal Care Margin Hits 20% as Gentiva Deal Expands Scale
  August 06, 2024 · ADUS
• BrainsWay (BWAY) Q2 2024: 28% Revenue Growth Propels Deep TMS Install Base Past 1,200
  August 06, 2024 · BWAY
• Broadridge (BR) Q4 2024: Closed Sales Surge 39%, Underpinning Multi-Year Growth Visibility
  August 06, 2024 · BR
• Acadia Pharmaceuticals (ACAD) Q2 2024: Nuplazid Guidance Raised $30M as DTC Campaigns Target Underpenetrated Markets
  August 06, 2024 · ACAD